These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9890529)

  • 21. Animal virus contaminants of biotechnology products.
    Onions D
    Dev Biol (Basel); 2004; 118():155-63. PubMed ID: 15645686
    [No Abstract]   [Full Text] [Related]  

  • 22. Re-processing of biological products: regulatory considerations from the CBER perspective.
    Shacter E
    Dev Biol (Basel); 2003; 113():105-7; discussion 115-6. PubMed ID: 14620859
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of product comparability.
    Builder SE
    Dev Biol Stand; 1998; 96():83-90. PubMed ID: 9890520
    [No Abstract]   [Full Text] [Related]  

  • 24. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 25. Viral validation design of a manufacturing process.
    Larzul D
    Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
    [No Abstract]   [Full Text] [Related]  

  • 27. [Special quality requirements in raw materials. Safety of biological products].
    MMW Munch Med Wochenschr; 1980 Jan; 122(1):26. PubMed ID: 6767914
    [No Abstract]   [Full Text] [Related]  

  • 28. Current and future approaches to ensure the viral safety of biopharmaceuticals.
    Brorson K; Norling L; Hamilton E; Lute S; Lee K; Curtis S; Xu Y
    Dev Biol (Basel); 2004; 118():17-29. PubMed ID: 15645669
    [No Abstract]   [Full Text] [Related]  

  • 29. Relationship between nature and source of risk and process validation.
    Berthold W; Werz W; Walter JK
    Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
    [No Abstract]   [Full Text] [Related]  

  • 30. An industry perspective on plasma-derived products.
    von Hoegen I
    Dev Biol (Basel); 2004; 118():31-5. PubMed ID: 15645670
    [No Abstract]   [Full Text] [Related]  

  • 31. Virus removal by filtration.
    Graf EG; Jander E; West A; Pora H; Aranha-Creado H
    Dev Biol Stand; 1999; 99():89-94. PubMed ID: 10404880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-processing strategies for biologicals API manufacturing processes.
    Opitz U
    Dev Biol (Basel); 2003; 113():101-4; discussion 115-6. PubMed ID: 14620858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of criteria for determining comparability of "well-characterized" proteins.
    Cavagnaro JA
    Dev Biol Stand; 1998; 96():79-81. PubMed ID: 9890519
    [No Abstract]   [Full Text] [Related]  

  • 38. [Viral safety concept: application to blood and blood products].
    Trouvin JH
    Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
    Xu Y; Brorson K
    Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New drug approval process in Japan.
    Hayakawa T
    Curr Opin Biotechnol; 1999 Jun; 10(3):307-11. PubMed ID: 10361082
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.